Following the close of the asset divestment, SDIX
will change its name to Special Diversified Opportunities Incorporated (SDOI).
When announcing the agreement, SDIX
commented that as part of OriGene, the target would be able to reach a wider range of customers and would have a better access to markets, which would be impossible if it remained as a standalone business.
Romer Labs noted that it will also take over all the staff members of the SDIX
food safety and GMO division, including those in R&D, sales & marketing and production.
Over the past seven years, SDIX
has incorporated its RapidChek E.
At closing, SDIX
will have no operations and its board will study alternatives for its cash and public company status, it said.
is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the pharmaceutical, biotechnology, diagnostics, and food safety markets.
Once the sale is completed, which is expected to happen during the fourth quarter of the year, SDIX
will focus on its life sciences activities.
As part of the agreement, OriGene is acquiring substantially all of the assets of SDIX
and has agreed to offer employment to a substantial majority of SDIX